Biochemical and Biophysical Research Communications
Volume 126, Issue 1, 16 January 1985, Pages 78-82
Irreversible inactivation of rat gastric (H+-K+)-ATPase by omeprazole
References (16)
- et al.
Biochem. Biophys. Acta
(1973) - et al.
J. Biol. Chem
(1976) - et al.
Biochim. Biophys. Acta
(1984) - et al.
Biochim. Biophys. Acta
(1977) - et al.
Biochim. Biophys. Acta
(1981) - et al.
J. Biol. Chem
(1981) - et al.
Biochim. Biophys. Acta
(1983) - et al.
Gastroenterol
(1983)
There are more references available in the full text version of this article.
Cited by (84)
Pharmacokinetics of omeprazole after intravenous and oral administration to rats with liver cirrhosis induced by dimethylnitrosamine
2007, International Journal of PharmaceuticsCharacterization of the inhibitory activity of tenatoprazole on the gastric H<sup>+</sup>,K<sup>+</sup>-ATPase in vitro and in vivo
2006, Biochemical PharmacologyCitation Excerpt :Thermolysin digestion of TM5/6 labeled by tenatoprazole shows that tenatoprazole labeled both Cys813 and Cys822, as previously found for pantoprazole labeling [10]. No reversal of the inhibited pump by PPIs is seen even after overnight incubation of the inhibited enzyme in vitro [27–29]; hence, the disulfide bonds are stable in the absence of disulfide reducing agents. If synthesis of new pump protein is the only means of generation of active enzyme, in vivo, covalent inhibition of the enzyme would be reversed only by de novo pump synthesis.
Molecular and Cellular Targets in Therapy of Acid-Related Diseases
2006, Therapy of Digestive DisordersPotassium-competitive acid blockade: A new therapeutic strategy in acid-related diseases
2005, Pharmacology and TherapeuticsMolecular and cellular targets in therapy of acid-related diseases
2005, Therapy of Digestive Disorders, Second Edition
Copyright © 1985 Published by Elsevier Inc.